Annals of Oncology – 2023
Use of existing drugs before the standard treatment for cervical cancer could lead to a reduction of about one-third in the risk of the disease recurring or causing death, the results of a study suggest.
Researchers assessed whether a short course of induction chemotherapy (IC), using cheap, already approved drugs to destroy as many cancer cells as possible, could reduce rates of relapse and death if administered before chemoradiation (CRT), a combination of chemotherapy and radiotherapy.
Cancer Research UK said the results were “remarkable”.
The trial found that after five years, 80% of those who received IC plus CRT were alive and 73% had not seen their cancer return or spread. In those who just had the standard treatment, 72% were alive and 64% had not seen their cancer return or spread.